Patient data support this conclusion where breast tumors with decreased expression of FOXA1 were less proliferative, had reduced ERBB2/ERBB3 (HER2/HER3) expression, and increased enrichment of immune signatures [167]. Here, ERBB2 is linked to breast neoplasm.